secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2022-10-06T23:59:59+00:00
Accession:  0001140361-22-036339
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics reports positive DSMB outcome for NAVIGATE study of belapectin in NASH cirrhosis
--------------------------------------------------------------------------------

- Second DSMB meeting recommends study continue as designed without modifications.
- NAVIGATE is a seamless adaptive Phase 2b/3 trial of belapectin for primary prevention of esophageal varices in NASH cirrhosis.
- Enrollment: 258 patients randomized; 74 in screening; full enrollment expected around year-end 2022.
- DSMB confirms belapectin appears safe and well tolerated in fragile cirrhotic patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036122036339/0001140361-22-036339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036122036339/brhc10042729_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-036339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer